极低碳水化合物饮食与钠-葡萄糖协同转运蛋白2抑制剂：与酮症酸中毒相关的双重风险
Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis.
作者信息
Tougaard Ninna Hahn, Faber Jens, Eldrup Ebbe
机构信息
Department of Endocrinology, Herlev Hospital, Herlev, Denmark.
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
出版信息
BMJ Case Rep. 2019 Apr 5;12(4):e227516. doi: 10.1136/bcr-2018-227516.
Abstract
Diabetic euglycaemic ketoacidosis is a possible adverse effect of sodium-glucose co-transporter-2 inhibitors (SGLT2i). We report a case in which the combination of SGLT2i and a strict very low-carbohydrate diet led to severe diabetic ketoacidosis in a young Caucasian man with type 2 diabetes.
摘要
糖尿病正常血糖性酮症酸中毒是钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）的一种可能的不良反应。我们报告了一例2型糖尿病的年轻白种男性病例，其SGLT2i与严格的极低碳水化合物饮食相结合导致了严重的糖尿病酮症酸中毒。
相似文献
1
Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis.
BMJ Case Rep. 2019 Apr 5;12(4):e227516. doi: 10.1136/bcr-2018-227516.
2
[Life-threatening ketoacidosis in patients with type 2 diabetes on LCHF diet].
Lakartidningen. 2018 Jun 29;115:E4AD.
3
Sodium-glucose co-transporter 2 inhibitors in the peri-operative period: A warning to all clinicians.
BJU Int. 2019 May;123 Suppl 5:6-7. doi: 10.1111/bju.14766.
4
[Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report].
Yakugaku Zasshi. 2019;139(11):1479-1483. doi: 10.1248/yakushi.19-00120.
5
Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
CMAJ. 2021 Sep 7;193(35):E1385-E1388. doi: 10.1503/cmaj.202627.
6
[Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
Rev Med Interne. 2020 Apr;41(4):226-231. doi: 10.1016/j.revmed.2019.12.006. Epub 2019 Dec 19.
7
Low carbohydrate diet while taking dapagliflozin: A case report and review of literature.
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):361-363. doi: 10.1016/j.dsx.2021.01.016. Epub 2021 Jan 23.
8
SGLT-2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient.
BMJ Case Rep. 2022 Sep 16;15(9):e250233. doi: 10.1136/bcr-2022-250233.
9
Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment.
Expert Opin Drug Saf. 2020 Jun;19(6):673-682. doi: 10.1080/14740338.2020.1764532. Epub 2020 Jun 10.
10
Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
Diabetes Obes Metab. 2017 May;19(5):739-743. doi: 10.1111/dom.12848. Epub 2017 Feb 21.
引用本文的文献
1
Nutritional assessment and medical dietary therapy for management of obesity in patients with non-dialysis chronic kidney disease: a practical guide for endocrinologist, nutritionists and nephrologists. A consensus statement from the Italian society of endocrinology (SIE), working group of the club nutrition-hormones and metabolism; the Italian society of nutraceuticals (SINut), club ketodiets and nutraceuticals "KetoNut-SINut"; and the Italian society of nephrology (SIN).
J Endocrinol Invest. 2024 Dec;47(12):2889-2913. doi: 10.1007/s40618-024-02446-8. Epub 2024 Sep 18.
2
Evidence-based European recommendations for the dietary management of diabetes.
Diabetologia. 2023 Jun;66(6):965-985. doi: 10.1007/s00125-023-05894-8.
3
Current Evidence Concerning Effects of Ketogenic Diet and Intermittent Fasting in Patients with Nonalcoholic Fatty Liver.
J Clin Transl Hepatol. 2022 Aug 28;10(4):730-739. doi: 10.14218/JCTH.2021.00494. Epub 2022 May 6.
4
An Unsuspected Case of Euglycemic Diabetic Ketoacidosis With Twists.
Cureus. 2022 Apr 10;14(4):e24016. doi: 10.7759/cureus.24016. eCollection 2022 Apr.
5
Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission.
Diabetologia. 2022 Jan;65(1):14-36. doi: 10.1007/s00125-021-05577-2. Epub 2021 Nov 17.
6
Strawberry pink blood: hypertriglyceridaemia and diabetic ketoacidosis secondary to poorly controlled type 2 diabetes mellitus.
BMJ Case Rep. 2021 Aug 20;14(8):e243696. doi: 10.1136/bcr-2021-243696.
7
A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed.
Case Rep Endocrinol. 2020 Aug 13;2020:8832833. doi: 10.1155/2020/8832833. eCollection 2020.
8
Scientific evidence underlying contraindications to the ketogenic diet: An update.
Obes Rev. 2020 Oct;21(10):e13053. doi: 10.1111/obr.13053. Epub 2020 Jul 10.
9
Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report.
Clin Pract Cases Emerg Med. 2020 Apr 23;4(2):185-188. doi: 10.5811/cpcem.2020.2.45904. eCollection 2020 May.
10
Low-Carbohydrate and Very-Low-Carbohydrate Diets in Patients With Diabetes.
Diabetes Spectr. 2020 May;33(2):133-142. doi: 10.2337/ds19-0070.
本文引用的文献
1
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Lancet Diabetes Endocrinol. 2018 May;6(5):370-381. doi: 10.1016/S2213-8587(18)30023-8. Epub 2018 Feb 23.
2
The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.
Can J Diabetes. 2017 Oct;41(5):517-523. doi: 10.1016/j.jcjd.2017.08.241.
3
Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
Diabetes Obes Metab. 2017 May;19(5):739-743. doi: 10.1111/dom.12848. Epub 2017 Feb 21.
4
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016. doi: 10.1016/S2213-8587(16)30267-4. Epub 2016 Sep 16.
5
Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet.
J Diabetes Investig. 2015 Sep;6(5):587-90. doi: 10.1111/jdi.12330. Epub 2015 Feb 20.
6
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.
Diabetes Care. 2015 Sep;38(9):1638-42. doi: 10.2337/dc15-1380.
7
Acute intractable vomiting and severe ketoacidosis secondary to the Dukan Diet©.
J Emerg Med. 2014 Oct;47(4):e109-12. doi: 10.1016/j.jemermed.2014.06.020. Epub 2014 Aug 22.
8
Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3.
9
A life-threatening complication of Atkins diet.
Lancet. 2006 Mar 18;367(9514):958. doi: 10.1016/S0140-6736(06)68394-3.
10
Ketoacidosis during a low-carbohydrate diet.
N Engl J Med. 2006 Jan 5;354(1):97-8. doi: 10.1056/NEJMc052709.
Zotero 插件